Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 7:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Lung Large Cell Carcinoma Clear all
Completed Phase 1Phase 2 Interventional Results available

Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017

NCT03003468
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Imprime PGG, MK-3475
Drug
Lead sponsor
Lawrence Feldman, MD
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
5
States / cities
Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Jul 23, 2026, 7:39 AM EDT
Completed Phase 2 Interventional Results available

Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT01557959
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
cisplatin, pegfilgrastim, erlotinib hydrochloride, laboratory biomarker analysis, polymorphism analysis, pharmacogenomic studies, genetic linkage analysis, docetaxel
Drug · Biological · Other + 1 more
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Jul 23, 2026, 7:39 AM EDT
Completed Phase 3 Interventional

Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

NCT00006484
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, tirapazamine
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
93
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced Jul 23, 2026, 7:39 AM EDT
Completed Phase 2 Interventional

Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer

NCT00006019
View directory record Official record
Conditions
Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Prostate Cancer
Interventions
azacitidine, sodium phenylbutyrate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced Jul 23, 2026, 7:39 AM EDT
Terminated Phase 3 Interventional Results available

Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer

NCT00863512
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, docetaxel, gemcitabine hydrochloride, pemetrexed disodium, vinorelbine tartrate, standard follow-up care
Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
93
States / cities
Anniston, Alabama • Birmingham, Alabama • Burbank, California + 66 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Jul 23, 2026, 7:39 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Metastatic Cancer

NCT00020267
View directory record Official record
Conditions
Lung Cancer, Adult Soft Tissue Sarcoma, Colorectal Cancer, Bone Cancer, Ovarian Sarcoma, Melanoma, Colon Cancer, Rectal Cancer, Breast Cancer, Eye Cancer, Uterine Sarcoma
Interventions
interleukin-2, MAGE-12 peptide vaccine, Montanide ISA-51
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Timeline
Started 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2024 · Synced Jul 23, 2026, 7:39 AM EDT
Completed Phase 2 Interventional Results available

Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed By Surgery

NCT00551369
View directory record Official record
Conditions
Lung Cancer
Interventions
SBRT
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
19
States / cities
Birmingham, Alabama • Berkeley, California • Carmichael, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Jul 23, 2026, 7:39 AM EDT
Completed Phase 3 Interventional

Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation

NCT00004230
View directory record Official record
Conditions
Cancer
Interventions
captopril, cyclophosphamide, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Jul 23, 2026, 7:39 AM EDT
Completed Phase 3 Interventional Results available

Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery

NCT00003901
View directory record Official record
Conditions
Lung Cancer
Interventions
immunohistochemistry staining method, biopsy, surgery
Other · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2011
U.S. locations
56
States / cities
Mobile, Alabama • Los Angeles, California • Pasadena, California + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Jul 23, 2026, 7:39 AM EDT
Completed Phase 3 Interventional

Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery

NCT00003387
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, chemotherapy, paclitaxel, radiation therapy
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
47
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Jul 23, 2026, 7:39 AM EDT
Active, not recruiting Phase 1 Interventional

DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer

NCT05680922
View directory record Official record
Conditions
Small Cell Lung Cancer Extensive Stage, Large Cell Neuroendocrine Carcinoma of the Lung
Interventions
LB2102
Biological
Lead sponsor
Legend Biotech USA Inc
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
Tampa, Florida • Lexington, Kentucky • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Jul 23, 2026, 7:39 AM EDT
Completed Phase 2 Interventional

Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC

NCT04010357
View directory record Official record
Conditions
Small-cell Lung Cancer, Large Cell Neuroendocrine Carcinoma of the Lung, Extrapulmonary Small Cell Carcinoma
Interventions
Abemaciclib,
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 23, 2026, 7:39 AM EDT
Completed Phase 2 Interventional Results available

TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

NCT00563784
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Lung Cancer
Interventions
Erlotinib, Carboplatin, Paclitaxel, Radiation Therapy
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Jul 23, 2026, 7:39 AM EDT
Completed Phase 1 Interventional Results available

Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

NCT01302808
View directory record Official record
Conditions
Lung Cancer, Metastatic Cancer
Interventions
Erlotinib plus Romidepsin (8 mg/m^2), Erlotinib plus Romidepsin (10 mg/m^2), Erlotinib plus Romidepsin (10 mg/m^2) + Antiemetic prophylaxis, (Erlotinib plus Romidepsin (8mg/m^2)) + Antiemetic prophylaxis
Combination Product
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Jul 23, 2026, 7:39 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

NCT07707895
View directory record Official record
Conditions
Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology, Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology
Interventions
Obrixtamig, ZL-1310, Atezolizumab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 23, 2026, 7:39 AM EDT
Not listed Phase 2 Interventional

Docetaxel Plus Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

NCT00003562
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, docetaxel
Drug
Lead sponsor
Hope Cancer Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
2
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Jul 23, 2026, 7:39 AM EDT
Completed Phase 3 Interventional Results available

ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures

NCT00404924
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
ZD6474 (vandetanib), Best Supportive Care
Drug · Other
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
1,140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
2
States / cities
Tucson, Arizona • Germantown, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Jul 23, 2026, 7:39 AM EDT
Terminated Phase 2 Interventional Results available

An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations

NCT01646125
View directory record Official record
Conditions
Advanced Non Small Cell Lung Cancer (NSCLC)
Interventions
AUY922, Docetaxel, Pemetrexed
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Los Angeles, California • Rockville, Maryland • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Jul 23, 2026, 7:39 AM EDT
Completed Phase 1 Interventional

Topotecan and Radiation Therapy in Treating Patients With Solid Tumors or Lymphoma

NCT00002625
View directory record Official record
Conditions
Esophageal Cancer, Lung Cancer, Lymphoma
Interventions
topotecan hydrochloride, low-LET electron therapy, low-LET photon therapy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2000
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Jul 23, 2026, 7:39 AM EDT
No Longer Available No phase listed Expanded access

An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer

NCT02784158
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Lung Cancer, Advanced Malignancies, Carcinoma
Interventions
Brigatinib
Drug
Lead sponsor
Ariad Pharmaceuticals
Industry
Eligibility
18 Years and older
U.S. locations
3
States / cities
La Jolla, California • Orange, California • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Jul 23, 2026, 7:39 AM EDT
Completed Phase 2 Interventional Results available

Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

NCT00445965
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin), Metastatic Cancer, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma, Small Intestine Cancer
Interventions
DNA analysis, immunologic technique, pharmacological study, iodine I 131 monoclonal antibody 3F8, 131I-3F8
Genetic · Other · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Jul 23, 2026, 7:39 AM EDT
Not listed Phase 1 Interventional

Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features

NCT00314925
View directory record Official record
Conditions
Carcinoid, Neuroendocrine
Interventions
Seneca Valley Virus (biological agent)
Drug
Lead sponsor
Neotropix
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
10
States / cities
Ocoee, Florida • Indianapolis, Indiana • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2010 · Synced Jul 23, 2026, 7:39 AM EDT
Completed Phase 2 Interventional

Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer

NCT00003666
View directory record Official record
Conditions
Lung Cancer
Interventions
6-hydroxymethylacylfulvene
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
48
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Jul 23, 2026, 7:39 AM EDT
Terminated Phase 2 Interventional Results available

S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib

NCT02134912
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
crizotinib, pemetrexed disodium, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
167
States / cities
Sacramento, California • Aurora, Colorado • Colorado Springs, Colorado + 111 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Jul 23, 2026, 7:39 AM EDT